Abstract: The system is a self-oxidation internal heating steam reforming system for conducting self-oxidation of a raw material gas under the presence of oxygen and conducting steam reforming to generate a hydrogen-rich reformed gas. The system includes a steam generator including a combustion section for combusting an air-fuel mixture obtained by mixing a combustion air with a fuel, thereby heating water using a combustion gas generated in the combustion section to generate hydrogen; a first sucking-mixer for sucking the raw material gas into a steam stream coming from the steam generator to obtain a raw material-steam mixture; and a reformer for oxidizing the raw material gas in the raw material-steam mixture by an oxygen-containing gas supplied from outside, thereby conducting steam reforming of the raw material gas using the reaction heat of the oxidation to generate a hydrogen-rich reformed gas.

Abstract: The invention provides a method for consistently producing a hydrogen gas separator with a good performance balance. The method includes the process for preparing a porous substrate and the process for forming a silica coat on the substrate by chemical vapor deposition in which a reaction is brought about between a silica source provided to one side of the substrate and an oxygen-containing gas supplied to the other side of the substrate. The vapor deposition process is carried out using as the silica source a silicon compound (a) with Si-Z-Si bonds (Z is O or N) in the molecule.

Abstract: A redundant changeover apparatus causing no frame synchronization loss even upon occurrence of changeover between working system and protection system. In case of an in-apparatus synchronization system, when two input signals which are mutually asynchronous in phase are changed over by a changeover switch, a changeover switch, a clock extractor, a PLL circuit, and a clock changing portion transmit signals with clocks before the changeover being gradually changed to clocks after the changeover. Alternatively, in case of an in-apparatus synchronize system, data are separated from clocks so that the data are once changed to data with reference clocks, and then for the data, clocks before the changeover are gradually changed to clocks after the changeover.

Abstract: The steam reformer 1 has a double-cylinder structure having an inner cylinder 2 and an outer cylinder 3 surrounding the inner cylinder 2. The inner cylinder 2 contains a high-temperature reaction section 6 and an adjacent section 7 being adjacent to the high-temperature reaction section 6. The high-temperature reaction section 6 contains a mixed-catalyst bed 4 prepared by mixing a steam reforming catalyst and an oxidation catalyst, and an oxygen-containing gas introduction section 5. A heat transfer suppresser 50 is structured to suppress heat transfer from the high-temperature reaction section 6 to the adjacent section 7 or to the oxygen-containing gas introduction section 5. With the heat-transfer suppressor 50, the thermal diffusion from the high-temperature reaction section 6 to peripheral area is effectively suppressed.

Abstract: The system is a self-oxidation internal heating steam reforming system for conducting self-oxidation of a raw material gas under the presence of oxygen and conducting steam reforming to generate a hydrogen-rich reformed gas. The system includes a steam generator including a combustion section for combusting an air-fuel mixture obtained by mixing a combustion air with a fuel, thereby heating water using a combustion gas generated in the combustion section to generate hydrogen; a first sucking-mixer for sucking the raw material gas into a steam stream coming from the steam generator to obtain a raw material-steam mixture; and a reformer for oxidizing the raw material gas in the raw material-steam mixture by an oxygen-containing gas supplied from outside, thereby conducting steam reforming of the raw material gas using the reaction heat of the oxidation to generate a hydrogen-rich reformed gas.

Abstract: Novel epoxysuccinamide derivatives represented by the general formula (1) or physiologically acceptable salts thereof, which are useful particularly as remedies for bone diseases and arthritis, wherein R1 and R3 are each hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or a heterocyclic-alkyl group; R2 is alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or a hetericyclic-alkyl group; X is —O— or —NR4— (wherein R4 is hydrogen, alkyl, aryl, aralkyl, a heterocyclic group, or a heterocyclic-alkyl group; Y1 is OR5, SR6, or NR7R8 (wherein each of R5, R6 and R7 is hydrogen, alkyl, aryl, aralkyl, acyl, a heterocyclic group, or a heterocyclic-alkyl group, and R8 is the same as defined for R4); and Y2 is hydrogen or alkyl, or alternatively Y1 and Y2 can be combined to form ═O, ═S, ═N—R9, or ═N—OR10 (wherein each of R9 and R10 is the same as defined for R4), provided that each of the alkyl, aryl and heterocyclic groups defined fo

Abstract: The present invention provides a receiver apparatus for receiving digital data in which stuff data have been inserted by stuffing synchronization. The receiver apparatus has a memory unit having a plurality of memory cells. The digital data other than the stuff data are written in the memory unit in synchronization with a write clock signal, and read from the memory cell in synchronization with a read clock signal. The cycle of the read clock signal is adjusted on the basis of an interval from a reading address to an writing address of the memory cell.

Abstract: A redundant changeover apparatus causing no frame synchronization loss even upon occurrence of changeover between working system and protection system. In case of an in-apparatus synchronization system, when two input signals which are mutually asynchronous in phase are changed over by a changeover switch, a changeover switch, a clock extractor, a PLL circuit, and a clock changing portion transmit signals with clocks before the changeover being gradually changed to clocks after the changeover. Alternatively, in case of an in-apparatus synchronize system, data are separated from clocks so that the data are once changed to data with reference clocks, and then for the data, clocks before the changeover are gradually changed to clocks after the changeover.

Abstract: Novel epoxysuccinamide derivatives represented by the general formula (1) or physiologically acceptable salts thereof, which are useful particularly as remedies for bone diseases and arthritis, wherein R1 and R3 are each hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or a heterocyclic-alkyl group; R2 is alkyl, alkenyl, alkynyl, aryl, aralkyl, a heterocyclic group, or a hetericyclic-alkyl group; X is —O— or —NR4— (wherein R4 is hydrogen, alkyl, aryl, aralkyl, a heterocyclic group, or a heterocyclic-alkyl group; Y1 is OR5, SR6, or NR7R8 (wherein each of R5, R6 and R7 is hydrogen, alkyl, aryl, aralkyl, acyl, a heterocyclic group, or a heterocyclic-alkyl group, and R8 is the same as defined for R4); and Y2 is hydrogen or alkyl, or alternatively Y1 and Y2 can be combined to form ═O, ═S, ═N—R9, or ═N—OR10 (wherein each of R9 and R10 is the same as defined for R4), provided that each of the alkyl, aryl and heterocyclic groups defined fo

Abstract: Epoxysuccinamide derivatives of the formula (1): wherein R1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or aralkyl; R2 is alkyl, alkenyl, alkynyl, aryl, or aralkyl; R3 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic, or heterocyclic-alkyl; X is —O— or —NR4— (R4 is hydrogen, alkyl, aryl, aralkyl, heterocyclic, or heterocyclic-alkyl); Y1 is OR5, SR6, or NR7R8; and Y2 is hydrogen or alkyl. The compounds are useful as remedies for bone diseases and arthritis.

Abstract: An epoxysuccinic acid derivative having the following formula: ##STR1## ?wherein R.sup.1 is hydrogen, alkyl, aryl, or aralkyl; each of R.sup.2 and R.sup.3 independently is aryl, aralkyl or alkyl; X is --O-- or --NR.sup.4 --; and R.sup.4 is hydrogen, alkyl, or aralkyl! is useful for prevention and treatment of bone diseases such as osteoporosis, malignant hypercalcemia and Paget's syndrome, and further useful for treatment of osteoarthritis and rheumatoid arthritis which are accompanied by abnormal enhancement of cathepsin L activity, and furthermore useful as a medicine for treating diseases in which cathepsin B and L participate, such as muscular dystrophy and muscular atrophy.

Abstract: A seat cushion pad supporting construction has a base frame having an opening, and a planar spring deck disposed substantially over the opening. The planar spring deck is formed of a rectangular boundary frame and flexible support members extending front-to-rear between front and rear boundary frame portions of the boundary frame. The flexible support members may be spring steel wires or flexible planar members made of synthetic resin, rubber or fabric. The spring deck is non-resiliently connected at its front boundary frame portion to a front portion of the base frame adjacent the opening to be vertically pivotable with respect to the front base frame portion. The rear boundary frame portion is resiliently connected by tension springs to a rear portion of the base frame adjacent the opening. Optional front and side protruding spring frames are connected to the boundary frame to support the upper legs of an occupant.

Abstract: A therapeutic agent for liver disease containing as an active ingredient a piperazine derivative having the formula: ##STR1## wherein, A represents a phenyl, p-benzoquinonyl or cumarinyl group which may have at least one substituent selected from the group consisting of halogen, alkyl, fluoroalkyl, formyl, alkoxycarbonyl, acyl, hydroxy, alkoxy, acyloxy, glycosyloxy, amino, alkylamino, mercapto, alkylthio and nitro; B represents a single bond or a straight chain alkylene group containing 1-4 carbon atoms which may have at least one substituent selected from the group consisting of alkyl, aryl, aralkyl, hydroxy and oxo; R represents an atom or a group selected from the group consisting of hydrogen, alkali metal, alkaline earth metal, alkyl, cycloalkyl, aralkyl and aryl; and n is 2 or 8, or its pharmaceutically acceptable salt is diclosed.

Abstract: A therapeutic agent for liver disease containing as an active ingredient a piperazine derivative having the formula: ##STR1## wherein, A represents a phenyl, p-benzoquinonyl or cumarinyl group which may have at least one substituent selected from the group consisting of halogen, alkyl, fluoroalkyl, formyl, alkoxycarbonyl, acyl, hydroxy, alkoxy, acyloxy, glycosyloxy, amino, alkylamino, mercapto, alkylthio and nitro; B represents a single bond or a straight chain alkylene group containing 1-4 carbon atoms which may have at least one substituent selected from the group consisting of alkyl, aryl, aralkyl, hydroxy and oxo; R represents an atom or a group selected from the group consisting of hydrogen, alkali metal, alkaline earth metal, alkyl, cycloalkyl, aralkyl and aryl; and n is 2 or 3, or its pharmaceutically acceptable salt is disclosed.